Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.45 |
| ▸ | GLA | P06280 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | BACE1 | P56817 | 2/20 | 0.41 |
| ▸ | KDM1A | O60341 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.39 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL5892410 | 0.91 | OPRL1 (0.41) | OPRL1HTTGLANPSR1CYP1A2 | |
| SCHEMBL737133 | 0.82 | P2RX7 (0.42) | OPRL1HTTGLANPSR1BCHE | |
| SCHEMBL64531 | 0.82 | GLA (0.56) | HTTGLANPSR1CYP1A2CYP3A4 | |
| SCHEMBL696339 | 0.82 | KDM1A (0.56) | CYP1A2CYP2C9CYP2C19BCHEACHE | |
| SCHEMBL736318 | 0.79 | CHRM3 (0.41) | HTTGLANPSR1BCHEACHE | |
| SCHEMBL696022 | 0.79 | GLA (0.45) | HTTGLANPSR1CYP1A2CYP2D6 | |
| SCHEMBL736271 | 0.79 | GLA (0.53) | OPRL1HTTGLANPSR1CYP3A4 | |
| SCHEMBL30606515 | 0.79 | GLA (0.53) | OPRL1HTTGLANPSR1CYP3A4 | |
| SCHEMBL737438 | 0.79 | P2RX7 (0.49) | — | |
| SCHEMBL5437369 | 0.77 | SIGMAR1 (0.44) | BCHEACHEBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1786814-B1 | BICYCLONONENE DERIVATIVES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-03-31 | — | — | EP | claimed |
| US-20090306123-A1 | Bicyclononene derivaties | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-12-10 | — | — | US | claimed |
| EP-1786814-A1 | BICYCLONONENE DERIVATIVES AS RENIN INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2007-05-23 | — | — | EP | claimed |
| WO-2006021402-A1 | BICYCLONONENE DERIVATIVES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-03-02 | — | — | WO | claimed |
| US-8138340-B2 | Bicyclononene derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-03-20 | — | — | US | disclosed |
| CN-101010323-B | Bicyclononene derivatives as renin inhibitors | ACTELION PHARMACEUTICALS LTD | 2010-06-16 | — | — | CN | disclosed |
| EP-1786814-B1 | BICYCLONONENE DERIVATIVES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-03-31 | — | — | EP | disclosed |
| US-20090306123-A1 | Bicyclononene derivaties | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-12-10 | — | — | US | disclosed |
| CN-101010323-A | Bicyclononene derivatives as renin inhibitors | ACTELION PHARMACEUTICALS LTD (CH) | 2007-08-01 | — | — | CN | disclosed |
| EP-1786814-A1 | BICYCLONONENE DERIVATIVES AS RENIN INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006021402-A1 | BICYCLONONENE DERIVATIVES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306123-A1 | Bicyclononene derivaties | REN, ACE, CYP51A1 | OPRL1 2310/4885HTT 3838/4885GLA 1344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.